Hypertension in Hemodialysis. An Overview on Physiopathology and Therapeutic Approach in Adults and Children

Rosario Cianci*,1, Silvia Lai, Laura Fuiano2, Antonietta Gigante1, Paola Martina1, Biagio Barbano1, Domenico Di Donato1, Gianfranco Clemenzia1, Pierangela Presta2, Paolo Gigliotti2, Michele Andreucci2, Alfredo Caglioti2 and Giorgio Fuiano2

1Viale dell 'Università', 37, Dipartimento di Medicina Clinica, 6 Clinica Medica, 00100, Rome, Italy
2University Magna Graecia, Catanzaro, Italy

Abstract: Chronic Kidney disease (CKD) patients, particularly those with end stage renal disease (ESRD), are at much higher risk of cardiovascular disease than the general population. Cardiovascular disease is by far the leading cause of morbidity and mortality in dialysis patients, accounting for almost 40% of hospitalizations and almost 50% of deaths.

Hypertension is the single most important factor for the development of cardio and cerebrovascular complications. The etio-pathogenesis of hypertension in dialysis patients is multifactorial, sodium excess and extracellular volume expansion is the major factor in the development of hypertension, however there are other pathogenetic factors that should be considered, such as renin-angiotensin system hyperactivity, increased sympathetic activity, altered endothelial cell function, hyperparathyroidism, and oxidative stress. The most important risk factors are anemia, hypoaalbuminemia, chronic inflammation, prothrombotic factors, hypermocysteinemia, vascular calcification and the traditional factors for cardiovascular risk (age, male gender, diabetes mellitus, dyslipidemia, smoke, physical inactivity, alcohol abuse).

Elevated blood pressure is frequent also in children on long term dialysis therapy. Data suggest that uremic factors or factors related to renal replacement therapy may be implicated in the pathogenesis of heart disease in adults and pediatric patients, because cardiovascular survival improves after transplantation.

The management of hypertension requires lifestyle modifications and control of volume status, with dietary salt and fluid restriction in combination with reduction of dialysate sodium concentration or with programmed “variable-sodium” dialysis.

The relationship between interdialytic weight and blood pressure is incompletely characterized; the dry weight (DW) method relies on the progressive reduction of the postdialysis body weight until blood pressure is normalized. There are several non clinical methods for evaluation DW such as measure the inferior vena cava diameter whit ultrasound, measure blood volume (BV) whit radiolabeled albumin and calculating post-hemodialysis BV from the change in hematocrit.

It may exist a lag time of several weeks between the normalization of the extracellular volume and blood pressure. It is related to the correction of the hemodynamic consequences of the extracellular volume overload.

The other problems to limit the possibility of correcting adequately volume expansion with dialysis are the use of anti-hypertensive drugs and the aggressive ultrafiltration required by short dialysis times. A possible treatment option for these patients may be increase time hemodialysis with slow, long hemodialysis; short, daily hemodialysis or nocturnal hemodialysis.

All classes of antihypertensive drugs can be used in dialysis patients, except the diuretics because inefficacy. Angiotensin-converting enzyme (ACE) and Angiotensin T1 receptor antagonist (AT1RA) appear to have the greatest ability to reduce left ventricular mass.

INTRODUCTION

Cardiovascular disease is the major cause of morbidity and mortality in patients with chronic kidney disease (CKD) Stage 5 and accounts for approximately 50% of deaths (KDOQI Guidelines) [1]. Overall, dialysis patients have a 10-20-fold increase in risk of death, compared with the general population [2]. In the recent HEMO study, the most common cause of death in dialyzed patients was ischemic heart disease (20.4 per cent) followed by cardiac rhythm disorders (10.4 per cent), cerebrovascular disease (8.6 per cent), and infections (7.7 per cent) [1]. The cardiovascular risk factors among patients with CKD Stage 5 may be divided into those that are nonspecific to kidney disease but are more prevalent, and those that are specific to CKD Stage 5. The latter are undoubtedly important, since patients with CKD Stage 5 have disease-related risk factors such as anemia, hyperhomocysteinemia, hyperparathyroidism, oxidative stress, hypoaalbuminemia, chronic inflammation, prothrombotic factors, among others. In addition, data suggest that uremic fac-
tors, or factors related to renal replacement therapy (RRT)/dialysis may be implicated in the pathogenesis of heart disease in patients treated by dialysis, because cardiovascular survival improves after transplantation even in high-risk patients [3]. However, in patients on dialysis there is also increased prevalence of many traditional factors for cardiovascular risk (age, male gender, hypertension, diabetes, dyslipidemia, and physical inactivity); among these, hypertension is the most important risk factor for the development of cardio and cerebrovascular complications, in other words the leading cause of morbidity and mortality in dialysis patients. However, despite the universally recognized detrimental effect of hypertension in dialysis patients, 60–70 per cent of patients reported on clinical studies performed in Europe as well as in North America remains hypertensive while undergoing hemodialysis (HD) [4] or peritoneal dialysis (PD) treatment. This has been demonstrated in most survival statistics [5]. The main cause of such a poor control has been identified as the difficulty in obtaining optimal dry weight, coupled with large inter-dialytic weight gain and unrestricted, often excessive dietary sodium intake [6].

**DISCUSSION**

Despite the common opinion that blood pressure (BP) is an important predictor for cardiovascular (CV) morbidity and mortality in dialysis populations, several studies failed to identify hypertension as having a major influence on CV risk in large cohorts of ESRD patients [7]. Duranti et al. retrospectively studied 370 chronic uremic patients to determine the number of mortalities due to hypertension. A total of 168 patients were found to be normotensive and 202 as hypertensive. No significant difference in survival was found between normotensive and hypertensive patients, even when other prognostic variables were considered in the statistical analysis. By contrast, very few observational studies have associated hypertension with shorter survival and excellent BP control with increased survival. Hypertension treated with antihypertensive medications unequivocally reduces cerebrovascular risk, but demonstration of a survival benefit for cardiovascular mortality has proven more difficult to demonstrate. In addition, the question is further complicated by the “reverse-epidemiology” in dialysis patients, since recent observational studies have demonstrated a paradoxical relationship between increasing blood pressure and increasing mortality, showing that a pre-dialysis systolic BP < 110 mmHg is significantly associated with a relevant increase of mortality and that the lowest mortality rate can be registered in patients with a pre-dialysis systolic BP between 150 and 159 mmHg [8, 9]. Kalantar-Zadeh et al. have recently analyzed in depth this paradoxical phenomenon, studying a 15-month cohort of 40933 hemodialysis patients in the United States whose predialysis and postdialysis blood pressure values were recorded routinely during each hemodialysis treatment [10]. The hazard ratio for all causes death for a predialysis systolic BP < 110 mmHg was 1.60. Adjustment for the malnutrition-inflammation-atherosclerosis complex [10,12]; (b) consequently, patients with lower BP may represent a sicker population, because of significant systolic dysfunction and left ventricular dilatation and malnutrition [13]; (c) the short follow-up period can affect the results, because low pre-dialysis BP values are predictive of death only in association with short observation periods. In contrast, long-term observation showed that patients with normal BP have reduced mortality, compared with those with higher BP.

However, these data are capable of causing confusion and, therefore, it is not surprising that optimum blood pressure control has not been established. Different factors contribute to this uncertainty, the most important being (a) the concerns about the correct method of BP measurement in these patients; (b) the conflicting results of the most recent studies that do not allow to establish how low BP should be targeted.

The best method and timing of BP measurement in hemodialysis patients are subject to controversy. The lack of standardization of BP measurement in the dialysis unit may lead to misdiagnosis, so close attention must be paid to technical methods to obtain BP. Usually BP is measured just before and after the dialysis session. However, Coomer et al. observed that, although predialysis and postdialysis BP (recorded by dialysis nurses) correlated significantly with mean BP, predialysis systolic BP (SBP) overestimated mean SBP by an average of 10 mm Hg, while postdialysis SBP underestimated mean SBP by an average of 7 mm Hg [14]. Thus, a composite of BP measurements over a period of 1 to 2 weeks rather than isolated readings should be used for guidance [15,16]. Interdialytic BP monitoring with an ambulatory BP monitor is the most reproducible method and is thought to best represent BP in dialysis patients. If available, ambulatory BP is a useful tool to evaluate the quality of BP control in the interdialytic period. Alternative forms of BP measurement, such as home BP, 20-minute postdialysis BP, and short (3-hour to 4-hour) ambulatory blood pressure monitoring (ABPM), could prove useful when feasible or available [17]. However, continuous monitoring is warranted in patients suspected of poor control, such as those with large interdialytic weight gain [17], the results being reasonably reproducible. A further, additional problem in the evaluation of BP measurements is that uremic patients can lose the usual diurnal variation in blood pressure, possibly leading to nocturnal hypertension [18]. Thus, even patients supposed to be well controlled with daytime BP measurements may be at risk for hypertension-induced cardiovascular morbidity [19]. Due to the complexity of dialysis patients, the correct target of blood pressure goals cannot be exactly the same of that indicated for general population. It should ideally be individualized, taking into account the patient’s cardiac and neurologic status, comorbidities and age. According to the clinical conditions of the patient a “normal” BP, defined as a mean ambulatory BP <140/90 mmHg during the day and <120/80 mmHg by night, is a reasonable target goal [20].

**PATHOGENESIS**

The etiology of hypertension in ESRD is multifactorial, as one or more of the following factors, summarized in Table 1,
Volume expansion is perhaps the major Abnormal rela-
Sympathetic overactivity renal ischemia induced by scarring plays a major role.

is not completely understood, but it is probable that regional
mechanism underlying such an inappropriate renin secretion the face of sodium excess or increased BV. The exact
tion of renin may, in some istance, be inappropriately high in
tients. This suggests that even "normal" plasma concentra-
renin activity (PRA) has been demonstrated in dialysis pa-
tionship between exchangeable sodium or BV and plasma
mechanism, removal of the excess sodium and attainment of
overload has led to the dry weight (DW) concept, which is
post dialysis body-weight that allows BP to remain nor-
the post dialysis body-weight that allows BP to remain nor-
mal until the next dialysis session. In fact, regardless of the
mechanism, removal of the excess sodium and attainment of
DW can result in the normalization of BP in more than 60
percent of dialysis-dependent patients. However, this also
means that a significant proportion of these patients remain
hypertensive despite having reached their DW. Clinically it’s
very difficult to know if DW is achieved because this is a
clinical definition. Therefore, besides volume expansion,
other pathogenic factors should be considered, and, if possi-
ble, corrected.

Renin-angiotensin system hyperactivity. Abnormal rela-
tionship between exchangeable sodium or BV and plasma
renin activity (PRA) has been demonstrated in dialysis pa-
tients. This suggests that even “normal” plasma concentra-
tion of renin may, in some instance, be inappropriately high in
the face of sodium excess or increased BV. The exact
mechanism underlying such an inappropriate renin secretion
is not completely understood, but it is probable that regional
renal ischemia induced by scarring plays a major role.

Increased sympathetic activity. Sympathetic overactivity
is a common finding in end-stage renal disease, correlating
with the increase in both vascular resistance and systemic
BP. This should originate in the diseased kidneys, since it is
not seen in bilaterally nephrectomized patients. It has been
hypothesized that the sympathetic hyperactivity is due to the
accumulation of uremic metabolites that activate chemore-
ceptors within the kidney, eliciting a neural reflex that stimu-
lates the cardiovascular centers in the brainstem. This hy-
pothesis is supported by rat studies showing that renal deaf-
fervation abrogates hypertension in the 5/6 nephrectomy
model of chronic renal insufficiency. Additional potential
mechanisms underlying Sympathetic overactivity includes
increased levels of angiotensin II and asymmetrical dimethy-
larginine and contributes to hypertension and cardiovascular
complications but its causes are not fully understood [22-24].

Altered endothelial cell function. An intriguing concept
regarding the pathogenesis of hypertension in end-stage re-
nal disease is the abnormal endothelial release of hemody-
amically active compounds. The pathogenic role of in-
creased concentrations of endothelin-1, a result of decreased
renal clearance or endothelial cell damage has been proposed
as a relevant hypertensive factor in these patients as well as
the accumulation of endogenous inhibitors of the vascular
endothelium-generated vasoactive compound nitric oxide
such as asymmetric-dimethyl arginine (1-ADMA) that is an
inhibitor of NO synthesis. This observation raises the possi-
bility that NO deficiency may contribute to the development
of hypertension in end-stage renal disease [25, 26].

Erythropoietin (EPO). An increase in BP of 10 mmHg or
more may occur in patients with renal failure who are treated
with EPO. The risk is greatest in those with rapid correction
of severe anemia and with preexistent hypertension. EPO
can lead to an increase in blood pressure; the mechanisms of
this effect are not entirely clear. By optimizing dialysis
regulation, giving EPO subcutaneously and in a fashion to increase hemo-
tcrit gradually, the occurrence of BP increases can be
minimized. Hypertension has not proved to be a serious
general problem in the EPO treated patient [27].

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Pathogenesis</th>
<th>Pathological Effects</th>
</tr>
</thead>
</table>
| Hypervolemia              | Altered sodium cellular transport           | Sodium balance positive and extracellu-
lar volume expand                         |
| Erythropoietin            | Rapid correction wht severe anemia          | Increased hematocrit                      |
| Altered endothelial cell function | Elevated concentration of endothelin 1 | Increased systemic vascular resistance   |
| Hyperparathyroidism       | Increased intracellular calcium             | Vascular calcification                    |
| Calcification of the arterial tree | Increased aortic stiffness                  | Increased systolic pressure and widening |
|                           | Reduced large and small vessel distensibility | of pulse pressure                         |
| Increased sympathetic activity | Accumulation of uremic metabolites         | Increased systemic vascular resistance   |
|                           | stimulates the cardiovascular               |                                          |
|                           |   centers in the brainstem                 |                                          |
| Renin-angiotensin system hyperactivity | Renal regional ischemia induced and        | Increased systemic vascular resistance   |
|                           |   inappropriate renin secretion             |                                          |

Table 1. The Etiopathogenesis of Hypertension in End Stage Renal Disease
Hyperparathyroidism, ESRD is frequently associated with secondary hyperparathyroidism which leads to increased intracellular calcium. It has been demonstrated that in patients with chronic renal failure is present a significant relation between intracellular calcium and PTH and between PTH and mean BP. In patients treated with vitamin D analogues mean BP decreased significantly and the changes in BP were strictly related with the changes in serum PTH and Ca++. However, the results concerning the effects of parathyroidectomy on BP are conflicting [29, 30], so that the role of hyperparathyroidism in the pathogenesis of hypertension in dialysis is still undefined. Extensive atherosclerosis and heavy vascular and valvular calcifications are common complications of ESRD and are very likely related to the high incidence of cardiovascular disease in these patients. The greatly increased incidence of cardiovascular disease is only partly explained by traditional risk factors for atherosclerosis. In ESRD, vascular calcification occurs both in the vascular intima layer and in the tunica media. Intimal calcification is disseminated and is characteristically associated with damaged and abnormally functioning endothelium, and macrophage and vascular smooth muscle cell (VSMC) infiltration typical of atherosclerosis. On the contrary, medial calcification occurs in patchy distribution and the most frequent cell types found in its vicinity are the VSMC and macrophage. The uremic state is associated with numerous metabolic abnormalities and endocrine disturbances primarily involving calcium and phosphorus metabolism. Furthermore, chronic kidney disease and dialysis are considered states of active and strong inflammatory response. These dysfunctions occur early in the course of renal failure and likely contribute to the development and progression of vascular calcification and atherosclerosis. For many years, vascular calcification was considered solely the result of a passive deposition of hydroxyapatite crystals in the arterial wall due to elevated calcium-phosphate ion product. However, a large body of evidence has now shown that this is a highly regulated process governed by factors that closely resemble calcium deposition in bone tissue. In fact, vascular calcification requires changes in the phenotype of VSMC and the expression of several proteins normally involved in bone metabolism. In the detection of vascular calcification in ESRD the modern imaging modalities and the therapeutic approaches are currently available to slow its progression.

Calcification of the arterial tree. Patients with end-stage renal disease are more likely to have an increase in pulse pressure and isolated systolic hypertension [15]. Why this occurs is incompletely understood but increased aortic stiffness appears to play an important role. Accelerated age-related changes in vascular stiffness, together with factors peculiar to uremia, lead to loss of large and small vessel distensibility and profound changes in circulatory function that includes an increase in systolic pressure and widening of the pulse pressure. Pulse wave velocity is an integrated index of vascular function and structure, and is a major determinant of systolic hypertension, thereby increasing left ventricular afterload, left ventricular hypertrophy and left ventricular oxygen consumption. Decreased diastolic blood pressure, another consequence of arterial stiffening, is associated with decreased coronary perfusion contributing to ischaemic heart disease and evolution of adaptive into maladaptive left ventricular hypertrophy. Aortic stiffness measurements could serve as an important tool in identifying end-stage renal disease patients at higher risk of cardiovascular disease.

HYPERTENSION IN PEDIATRIC PATIENTS

Elevated BP is frequent also in children on long-term dialysis therapy. However, the prevalence of hypertension and status of BP control in these patients are lacking. Using the North American Pediatric Renal Transplantation Cooperative Study database, Mitsnef et al determined the prevalence of hypertension and assessed risk factors for elevated BP during long-term dialysis therapy in children in a cohort including 3743 patients (age, 0 to 21 years). Uncontrolled hypertension was defined as BP equal to or greater than age, sex, and height-specific 95th percentiles; controlled hypertension was considered in children who were administered antihypertensive medications, but had BP less than the 95th percentile. A total of 76.6% of patients had either uncontrolled (56.9%) or controlled (19.7%) hypertension at baseline. Normotensive children at baseline had significant BP increases, whereas hypertensive children at baseline had significant BP decreases during the first year of dialysis therapy. BP did not change significantly after 1 year of dialysis therapy; 51% of patients had uncontrolled hypertension after 1 year of maintenance dialysis therapy. Logistic regression analysis shows that baseline hypertensive status and use of BP medications are both large significant risk factors for subsequent hypertension. Other risk factors include young age, acquired cause of renal failure, black race, duration of dialysis, and hemodialysis as a mode of renal replacement therapy [31]. Hypertension is very prevalent and difficult to control in children on dialysis therapy. In another study designed to identify risk factors for poor BP control in children on maintenance HD, 71 subjects receiving HD in ten dialysis units participating in the Midwest of USA were evaluated. For each HD session, data on pre- and post treatment weights and BP were recorded. Hypertension, defined as mean BP ≥95th percentile, was found in 59 of the subjects. 15.5% had prehypertension, defined as mean BP between the 90th and 95th percentile. BP significantly decreased at the end of a dialysis session; however, only 35% of hypertensive subjects normalized their BP. Hypertensive subjects were younger than no-hypertensive, had higher serum phosphorus, and had more post-treatment weight above estimated dry weight perhaps reflecting their hypertensive state. Logistic regression showed that younger age and higher serum phosphorus independently predicted hypertensive status. In conclusion, this study emphasizes the difficulty of BP control in pediatric HD patients [32]. However, also in a small cohort of pediatric patients on peritoneal dialysis the majority had BP abnormalities in which severity was most accurately assessed with ambulatory blood pressure monitoring. ABPM parameters were found to be significantly correlated with left ventricular mass index [33]. Therefore, hypertension in dialysis is a common and serious problem also in pediatric patients.

MANAGEMENT

The management of hypertension in the dialysis patients requires (a) lifestyle modifications and control of volume status with lifestyle modifications, (b) control of volume status with dialysis and (c) (if those measures are unsuccessful) the administration of antihypertensive drugs.
Lifestyle modifications and control of volume status with lifestyle modifications. Lifestyle modification includes measures that help to reduce BP as well as other CV risk factors. These measures are similar to those traditionally prescribed to patients of general population, but are particularly important in high-risk patients as the dialysis patients are.

Weight reduction. Overweight (body mass index [BMI] =25-30 kg/m²) and obesity (BMI >30 kg/m²) have become mass phenomena with a pronounced upward trend in prevalence in most countries throughout the world and are associated with increased cardiovascular risk and poor survival. In patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis an 'obesity paradox' has been consistently reported, i.e., a high BMI is incrementally associated with better survival. A similar obesity paradox has been described in patients with chronic heart failure as well as in 20 million members of other distinct medically 'at risk' populations in the USA. Possible causes of the reverse epidemiology of obesity include: (a) time-discrepancies between the competing risks for the adverse events that are associated with overnutrition and undernutrition; (b) sequestration of uremic toxins in adipose tissue; (c) selection of a gene pool favorable to longer survival in dialysis patients during the course of CKD progression, which eliminates over 95% of the CKD population before they commence maintenance dialysis therapy; (d) a more stable hemodynamic status; (e) alterations in circulating cytokines; (f) unique neurohormonal constellations; (g) endotoxin-lipoprotein interactions and (h) reverse causation [34]. This phenomenon, the obesity-survival paradox, is neither universally accepted nor completely understood. However, there is no doubt the a correct nutritional status with an appropriate BMI is associated with a better outcome and help to keep BP controlled, because the "reverse" epidemiology of obesity in dialysis patients is mainly explained by mal- or undernutrition [35].

Salt and fluid. Dietary salt and fluid restriction is one of the most important measures to control BP in dialysis patients. The patients should adhere to a restricted salt diet (1000 to 1500 mg of sodium/day), which also helps decrease thirst [36]. However, patient compliance is often suboptimal and a continuous education is essential to obtain a satisfactory adherence to a moderate dietary sodium (and water) intake.

Physical exercise. Regular exercise as a measure aimed at preventing renal failure results in a positive influence on blood pressure, a reduction in weight, reduction in peripheral insulin resistance, and a reduction in vessel rigidity. These effects result in improved cardiopulmonary function, muscular strength and quality of life [37].

Alcohol abuse. Alcoholism is not only common psychosocial disorder, but also an important CV risk factor. Moderation of alcoholic intake may also result in remarkable BP reduction. Statistical modeling indicates that a 2% reduction in BP for all adults if alcohol intake is avoided. The impact of alcoholism on the care of patients undergoing hemodialysis has been addressed in USA using the Michigan Alcoholism Screening Test (MAST), a 25-item questionnaire that has been validated in multiple trials. Forty-five patients (27.6%) scored 5 or greater on the MAST. The MAST-positive subjects were younger (age, 55 +/- 15 years versus 64 +/- 13 years) and prevalently men (58% versus 43%). A trend toward lower serum albumin level was evident in the men in the MAST-positive group. Therefore, such a high prevalence of alcoholism in the urban dialysis population suggests that dialysis patients should be screened for alcoholism and adequately treated [38, 39].

Tobacco use. Smoking has received surprisingly little research attention in dialysis populations, a group at monumental cardiovascular risk. In a recent study Medicare claims data were used to study associations between smoking and new-onset cardiovascular outcomes, and death in a prospective cohort (N= 4024). Of the participants, 56.4% were lifetime nonsmokers, 3.6% were smokers with unknown current status, 20% had quit for more than 1 year, 5.8% had quit less than 1 year ago, and 14.2% were current smokers. Subjects with cardiovascular disease at baseline were more likely to be former smokers (P< 0.001). When adjustment was made for baseline age, demographic variables, mode of dialysis therapy, and comorbidity, smoking status was associated with new-onset congestive heart failure (adjusted hazards ratio 1.59 comparing current to nonsmokers, P= 0.004), new-onset peripheral vascular disease (adjusted hazards ratio 1.68, P< 0.001), and mortality (adjusted hazards ratio 1.37, P< 0.001). Former smokers, in contrast, had adjusted event risks similar to lifelong nonsmokers. The purpose of another study was to analyse both cross-sectional associations and how longitudinal changes in lifestyle factors and to estimate the hazard ratios for all-cause mortality for the changes in lifestyle factors and self-reported hypertension during the same period of time.

The authors found that continuing to smoke or being physically inactive or having hypertension at both points in time were all associated with higher hazard ratios for all-cause mortality (1.6, 1.9 and 1.8 respectively). Therefore, smoking, altered fibrinogen levels and elevated systolic blood pressure, is a major, modifiable, cardiovascular risk factor in patients starting dialysis therapy [2, 40].

TREATMENT

Control of volume status. The total amount of sodium present in the body controls the extracellular volume. In advanced renal failure, sodium balance becomes positive and the extracellular volume expands. This leads to hypertension, and vascular changes that lead to adverse cardiovascular consequences in dialysis patients. Controlling the body sodium content and the extracellular volume allows one to better control hypertension and its consequences. This has led to the concept of dry weight, a crucial component of dialysis adequacy. It can be, in fact, defined DW as the postdialysis weight in which the patients remains normotensive without antihypertensive medication until the next dialysis [41], or as that body weight at the end of dialysis below which further reduction results in hypotension [35]. But the relative lack of accuracy of the clinical evaluation alone (and the physicians' progressive lack of interest in bedside examination) has led to several nonclinical methods of assessing DW in an effort to improve the assessment of fluid status in dialysis patients.

One problem is that volume expansion can persist even among those thought to have obtained dry weight. Katzarski et al., measuring the inferior vena cava diameter (IVCD) with ultrasound for the assessment of fluid status before,
during and after the dialysis session as well as pre-HD blood volume (BV) with radiolabeled albumin, and calculating post-HD BV from the change in hematocrit found that (a) body weight, blood pressure, BV, and IVCD decreased in the entire population; (b) BV was significantly larger in the hypertensive patients than in the normotensive patients both before and after dialysis; (c) BV was correlated with the mean BP before and after HD; (d) IVCD was larger in the hypertensive than in the normotensive patients before and after HD; (e) BV and IVCD decreased in parallel during HD and increased during 2 hours after HD due to refilling of the intravascular space, indicating that changes in IVCD reflect changes in BV; (f) at the end of HD, several patients had IVCD below the reference range but IVCD increased during the following 1 to 2 hours, in some patients to values above the reference range. IVCD measured at the end or shortly after HD may therefore be misleading in assessing dry weight. However these are not useful measures in the clinical practice, because they require adequate re-equilibration after dialysis and prior to taking the measurement but these results confirm that extracellular fluid overload plays an important role in the pathogenesis of dialysis-associated hypertension [42]. The importance of inadequate correction of volume expansion as a cause of inadequate control of BP is also witnessed by the results of studies assessing extracellular volume by measuring pre and postdialysis plasma atrial natriuretic peptide (ANP). Predialysis ANP levels were higher in the hypertensive patients and postdialysis levels normalized only in those with dialysis-sensitive hypertension [43].

The other problems that limit the possibility of correcting adequately volume expansion with dialysis are the use of antihypertensive drugs and the aggressive ultrafiltration required by short dialysis times.

The use of antihypertensive drugs. In patients already on hypertensive agents the control of fluid status should be attained by gradually tapering the dosage of medications when BP progressively decreases as a result of ultrafiltration. If during the interdialytic period BP remain normal and it does not exceed 160/95 mmHg immediate before the next dialysis session, it is reasonable to keep antihypertensive therapy withheld [35].

The aggressive ultrafiltration. The discontinuous nature of hemodialysis causes saw-tooth volume fluctuations. The simplest way to improve the tolerance to rapid fluid removal during hemodialysis procedure is to perform prolonged and/or more frequent hemodialysis. Available therapeutic options to normalize blood pressure in these patients include dietary salt and fluid restriction in combination with reduction of dialysate sodium concentration. A possible treatment option for these patients may be long, slow hemodialysis (3 x 8 h per week); short daily hemodialysis (2-3 h, 7 times per week); nocturnal hemodialysis (6-7 times overnight per week). The results obtained with a standard regimen of eight hours regimen, three times a week in the dialysis center of Tassin, France, confirm this observation. In fact, in this center, almost all patients maintained normotension without medications. These results have to be attributed mainly to optimal volume control, although other factors, such as better control of uremia, decreased afferent nerve activity and efferent sympathetic activation [44,45].

In addition, a better control of fluid and volume status with dialysis can be attained also reducing the dialysate sodium concentration. Flanigan et al. demonstrated that a "variable-sodium" dialysis program could reduce the blood pressure of dialysis patients without increasing dialysis morbidity. Dialysis with dialysate sodium of 140 mEq/L was compared with dialysis with a programmed exponential decrease of dialysate sodium from 155 mEq/L to 135 mEq/L. Dialysate sodium was then held constant at 135 mEq/L for the final half hour of dialysis. Eighteen patients completed the 7-month study, each receiving 3.5 months of experimental and 3.5 months of standard therapy. Programmed "variable-sodium" dialysis resulted in a reduction in antihypertensive drug use without alterations in predialysis blood pressure, interdialytic weight gain, ultrafiltration tolerance, or the frequency of symptomatic dialysis cramps or hypotension [46, 47].

Therapy with antihypertensive drugs. A necessary premise to the use of drug therapy for hypertension in hemodialysis patients is this: even when the measures treated previously are unsuccessful (and frequently they are), dietary sodium restriction, lifestyle modifications and changes in the dialysis strategy, including a sensible dialysate sodium prescription, are indispensable in the success for an antihypertensive drug therapy program [48]. The current pattern and utilization of antihypertensive drugs was recently reported in the multicenter trial called HEMO study: in the United States 72% of the hemodialysis patients received antihypertensive medication (48% were prescribed calcium antagonists, 24% angiotensin-converting enzyme (ACE) inhibitors, and 21% β-blockers) [49].

Choice of antihypertensive drugs. All classes of antihypertensive drugs can be used in dialysis patients, with the sole exception of diuretics, which are cot commonly used because of their lack of efficacy. Therefore, with the exceptions of diuretics, the criteria for drug selection are quite similar to those used in non-dialysis patients. Consequently, consideration should be given to the coexisting diseases, and, secondarily, to the patient’s demographic characteristics, risk profile and lifestyle [35,48]. The presence of coexisting diseases should be carefully evaluated before choosing antihypertensive drugs. Table 2 summarizes some recommendations in the most common clinical situations.

ACE inhibitors. ACE inhibitors are usually well tolerated. They are particularly indicated in patients with heart failure due to systolic dysfunction and in many patients after an acute myocardial infarction. Their use has been associated with reduced mortality in hypertensive patients undergoing regular dialysis treatment. In a recent observational study, 60 patients had been treated with ACE inhibitors (treated group) and 66 patients had not (untreated group). Blood pressure reduction was not significantly different between the treated and untreated groups. Nevertheless, comparing the treated group with the untreated group, mortality was decreased significantly in the treated group, with a risk reduction of 52%. In treated patients 65 years or younger, the absolute risk reduction of mortality was 79%. Although further research is needed, these preliminary findings suggest that ACE inhibitors, independently of their antihypertensive effect, may dramatically reduce mortality among chronic hemodialysis patients 65 years or younger [50]. Their proba-
Safety. The most important side effects described with the use of ACE-inhibitors in end stage renal failure are hyperkalemia, anaphylactoid reactions with negatively charged hemodialysis membranes or other biomaterials and exacerbation of anemia. Use of ACE inhibitors in maintenance dialysis patients is associated with a significantly higher incidence of clinically important hyperkalemia by inhibition of residual excretion of potassium in the colon, or the cellular uptake of potassium [48]. This effect can be usually prevented with dietetic interventions, but weekly potassium control in the first month of dialysis and monthly measurements thereafter are recommended [51].

The report of anaphylactoid reactions is limited to some patient treated with ACE-inhibitors while undergoing dialysis with a high-flux AN69 dialyzer. This reaction was probably mediated by des-Arg9-braykinin and was triggered by negatively charged biomaterial (as AN69 is). Thus, it can be prevented just avoiding these biomaterial in patients treated with ACE-inhibitors [52].

CONCLUSION

The etio-pathogenesis of hypertension in dialysis patients is multifactorial, sodium excess and extracellular volume expansion is the major factor in the development of hypertension, however there are other pathogenetic factors should be considered, such as renin-angiotensin system hyperactivity, increased sympathetic activity, altered endothelial cell function, hyperparathyroidism, and oxidative stress. The most important risk factors are anemia, hypoalbuminemia, chronic inflammation, prothrombotic factors, hyperomocisteinemia, vascular calcification and the traditional factors for cardiovascular risk (age, male gender, diabetes mellitus, dyslipidemia, smoke, physical inactivity, alcohol abuse). The management of hypertension requires lifestyle modifications (regular physical exercise, alcohol and tobacco avoidance), a good nutrition with an appropriated BMI and control of volume status, whit dietary salt and fluid restriction. Blood pressure is the key indicator of ECV and is used to set the body weight target, usually with a lag time. The problems that limit the possibility of correcting adequately volume expansion with dialysis are the use of antihypertensive drugs and the aggressive ultrafiltration required by short dialysis times. A possible treatment option for these patients may be

Table 2. Choice of Antihypertensive Drugs in Consideration of Frequently Coexisting Diseases

<table>
<thead>
<tr>
<th>Clinical Situation</th>
<th>Preferred Drug</th>
<th>Not Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angina Pectoris</td>
<td>β-blockers Calcium antagonists</td>
<td>Direct vasodilators</td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ATIRA</td>
<td></td>
</tr>
<tr>
<td>Post-Myocardial Infarction</td>
<td>Non intrinsic sympathomimetic</td>
<td>Direct vasodilators</td>
</tr>
<tr>
<td></td>
<td>activity-β-Blockers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ATIRA</td>
<td></td>
</tr>
<tr>
<td>Hypertrophic cardiomypathy with diastolic dysfunction</td>
<td>β-blockers Diltiazem Verapamil</td>
<td>Direct vasodilators α1-blockers</td>
</tr>
<tr>
<td>Heart failure (decreased left ventricular ejection fraction)</td>
<td>ATIRA</td>
<td>Labetalol Calcium-antagonists</td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors β-blockers</td>
<td></td>
</tr>
<tr>
<td>Bradicardia Heart block Sick sinus syndrome</td>
<td>Pacemaker Labetalol Verapamil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ATIRA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors Diltiazem</td>
<td></td>
</tr>
<tr>
<td>Asthma Chronic obstructive pulmonary disease</td>
<td>ACE inhibitors ATIRA Calcium antagonists</td>
<td>β-blockers; Labetalol</td>
</tr>
</tbody>
</table>
increase time hemodialysis with slow, long hemodialysis; short, daily hemodialysis or nocturnal hemodialysis and gradually tapering the dosage of medications when BP progressively decreases as a result of ultrafiltration. All classes of antihypertensive drugs can be used in dialysis patients, except the diuretics because inefficacy. ACE inhibitors and AT1RA appear to have the greatest ability to reduce left ventricular mass.

**ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD</td>
<td>Chronic Kidney disease</td>
</tr>
<tr>
<td>ESRD</td>
<td>End stage renal disease</td>
</tr>
<tr>
<td>DW</td>
<td>Dry weight</td>
</tr>
<tr>
<td>BV</td>
<td>Blood volume</td>
</tr>
<tr>
<td>ACE</td>
<td>Angiotensin-converting enzyme</td>
</tr>
<tr>
<td>AT1RA</td>
<td>Angiotensin T1 receptor antagonist</td>
</tr>
<tr>
<td>RRT</td>
<td>Renal replacement therapy</td>
</tr>
<tr>
<td>HD</td>
<td>Hemodialysis</td>
</tr>
<tr>
<td>PD</td>
<td>Peritoneal dialysis</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>CV</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic BP</td>
</tr>
<tr>
<td>ABPM</td>
<td>Ambulatory blood pressure monitoring</td>
</tr>
<tr>
<td>ECV</td>
<td>Extracellular volume excess</td>
</tr>
<tr>
<td>PRA</td>
<td>Plasma renin activity</td>
</tr>
<tr>
<td>1-ADMA</td>
<td>Asymmetric-dimethyl arginine</td>
</tr>
<tr>
<td>EPO</td>
<td>Erythropoietin</td>
</tr>
<tr>
<td>VSMC</td>
<td>Vascular smooth muscle cell</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>MAST</td>
<td>Michigan Alcoholism Screening Test</td>
</tr>
<tr>
<td>IVCD</td>
<td>Inferior vena cava diameter</td>
</tr>
<tr>
<td>ANP</td>
<td>Atrial natriuretic peptide</td>
</tr>
<tr>
<td>ACE</td>
<td>Angiotensin-converting enzyme</td>
</tr>
<tr>
<td>LVH</td>
<td>Left ventricular hypertrophy</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
</tbody>
</table>

**REFERENCES**


Hypertension in Hemodialysis


